Joseph Lehar

Joseph Lehar

UNVERIFIED PROFILE

Are you Joseph Lehar?   Register this Author

Register author
Joseph Lehar

Joseph Lehar

Publications by authors named "Joseph Lehar"

Are you Joseph Lehar?   Register this Author

32Publications

1259Reads

32Profile Views

Natural Language-based Machine Learning Models for the Annotation of Clinical Radiology Reports.

Radiology 2018 05 30;287(2):570-580. Epub 2018 Jan 30.

From the Departments of Radiology (J.Z., J.T., J.S., A.S.) and Neurosurgery (M.P., M.B., A.C., J.B., E.K.O.), Icahn School of Medicine, 1 Gustave Levy Pl, New York, NY 10029; and Department of Bioengineering and Bioinformatics, Boston University, Boston, Mass (J.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018171093DOI Listing
May 2018

Simulating Serial-Target Antibacterial Drug Synergies Using Flux Balance Analysis.

PLoS One 2016 28;11(1):e0147651. Epub 2016 Jan 28.

Technical University of Denmark, Novo Nordisk Foundation Center for Biosustainability, Hørsholm, Denmark.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147651PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731467PMC
July 2016

A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines.

PLoS One 2014 18;9(7):e103050. Epub 2014 Jul 18.

Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, Canada; Department of Urologic Sciences, the University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103050PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103868PMC
November 2015

Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.

Cancer Res 2014 Jun 18;74(12):3294-305. Epub 2014 Apr 18.

Authors' Affiliations: Oncology Department, Novartis Institutes for BioMedical Research; Zalicus Inc., Cambridge; and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0138-TDOI Listing
June 2014

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Mol Cancer Ther 2014 May 7;13(5):1117-29. Epub 2014 Mar 7.

Authors' Affiliations: Novartis Institutes for BioMedical Research, Disease Area Oncology; Novartis Institutes for BioMedical Research, Global Discovery Chemistry; Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry; Novartis Pharma AG, Oncology Translational Medicine, Basel, Switzerland; Novartis Pharma AG, Oncology Translational Medicine; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, Massachusetts; and Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Shangai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0865DOI Listing
May 2014

Recurrent, robust and scalable patterns underlie human approach and avoidance.

PLoS One 2010 May 26;5(5):e10613. Epub 2010 May 26.

Motivation and Emotion Neuroscience Collaboration, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010613PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879576PMC
May 2010

Therapeutic selectivity and the multi-node drug target.

Discov Med 2009 Dec;8(43):185-90

Department of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
December 2009

Combination chemical genetics.

Nat Chem Biol 2008 Nov;4(11):674-81

CombinatoRx Incorporated, 245 First Street, Cambridge, Massachusetts 02142, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nchembio.120
Publisher Site
http://dx.doi.org/10.1038/nchembio.120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712875PMC
November 2008

High-order combination effects and biological robustness.

Mol Syst Biol 2008 5;4:215. Epub 2008 Aug 5.

Discovery, CombinatoRx Inc., Cambridge, MA 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/msb.2008.51DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538911PMC
October 2008

Multi-target therapeutics: when the whole is greater than the sum of the parts.

Drug Discov Today 2007 Jan 28;12(1-2):34-42. Epub 2006 Nov 28.

CombinatoRx Inc., 245 First Street, Cambridge, MA 02142, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2006.11.008DOI Listing
January 2007

Systematic discovery of multicomponent therapeutics.

Proc Natl Acad Sci U S A 2003 Jun 10;100(13):7977-82. Epub 2003 Jun 10.

CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1337088100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164698PMC
June 2003